After a century of progress, biology still resists simplicity
How GLP-1s Offer Real-World Heart Protection The evidence that GLP1-s reduce the risk of heart attack and stroke comes from large cardiovascular outcomes trials designed to measure what researchers call MACE, major adverse cardiovascular events
No clinical trial has answered this question definitively yet, but the mechanistic rationale is compelling
This action was seen when DPP-4 inhibitors were used both as monotherapy and as add-on to other therapies, i.e., metformin, sulfonylureas, tiazolidinediones or exogenous insulin
GLP-1 (Glucagon-Like Peptide-1) as distributed by Peptides Lab UK is not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment
Retatrutide is a promising triple agonist weight loss medication that has shown impressive results in clinical trials